Add Formweb to your mobile device
System Formulary Update
Class Standardization: Protease Inhibitors (PIs)
Situation
The protease inhibitors class review standardization was approved at the System Pharmacy and Therapeutics Committee meeting in April 2024.
Background
The following therapeutic interchange was reviewed: atazanavir capsules, atazanavir oral powder, atazanavir-cobicistat tablets, darunavir oral suspension, darunavir tablets, darunavir-cobicistat tablets, darunavir-cobicistat-emtricitabine-tenofovir alafenamide tablets, fosemprenavir tablets, lopinavir-ritonavir oral solution, lopinavir-ritonavir tablets, nelfinavir tablets, ritonavir oral powder, ritonavir oral solution, ritonavir tablets, tipranavir capsules, and tipranavir oral solution
Assessment/ Recommendations:
System P&T voted to include the following products on the UNC Health System Drug Formulary:
- Darunavir 600 mg tablet
- Darunavir 800 mg tablet
- Ritonavir 100 mg tablet
- Lopinavir-ritonavir 400 mg-100 mg/5 mL oral solution
Therapeutic interchanges will also be included for the following:
| Non-Formulary Order |
Formulary Equivalent Order |
|
Darunavir 800 mg/cobicistat 150 mg (Prezcobix®) Combination tablet |
Equivalent dose darunavir tablet + cobicistat tablet |
|
Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg (Symtuza®) Combination tablet |
Equivalent dose darunavir tablet + cobicistat tablet + emtricitabine/TAF Combination tablet |
Formulary/Epic changes will Go-Live on Tuesday, June 18, 2024.